CaltechAUTHORS
Published June 2016 | Version Accepted Version
Journal Article Open

Synthetic Applications and Methodological Developments of Donor-Acceptor Cyclopropanes and Related Compounds

Creators

  • 1. ROR icon California Institute of Technology
  • 2. ROR icon Baylor University

Abstract

Donor-acceptor cyclopropanes are convenient precursors to reactive and versatile 1,3-dipoles, and have found application in the synthesis of a variety of carbo- and heterocyclic scaffolds. This perspective review details our laboratory's use of donor-acceptor cyclopropanes as intermediates toward the total synthesis of various natural products. We also discuss our work in the development of novel cycloadditions and rearrangements of donor-acceptor cyclopropanes and aziridines, as well as an example of an aryne insertion proceeding via fragmentation of a transient donor-acceptor cyclobutane.

Additional Information

© 2016 Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim. Received: November 9, 2015; Accepted: December 7, 2015; Article first published online: 27 Jan. 2016. The authors thank the coworkers whose efforts have made our contributions to the chemistry of donor-acceptor cyclopropanes and related compounds possible: Jennifer M. Chen, Robert A. Craig, II, Hans-Jürgen Dietrich, Julie A. Dixon, Brian D. Doan, John A. Enquist, Jr., Eric M. Ferreira, Alexander F. G. Goldberg, Timothy P. Heffron, Alexandra A. Holubec, Michael E. Meyer, Dejah T. Petsch, Derek A. Pflum, John H. Phillips, Richmond Sarpong, Mohammed F. Shamji, Grant M. Shibuya, Julius T. Su, Uttam K. Tambar, and Matthew M. Weiss. Financial support from the A. P. Sloan Foundation, Abbott, the American Cancer Society (JFRA-523), Amgen, Astellas Pharma, AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Caltech, the Camille and Henry Dreyfus Foundation, Eli Lilly, the Elsa U. Pardee Foundation, GlaxoSmithKline, Johnson & Johnson, Merck, the NIH-NIGMS (R01GM080269), Novartis, the NSF CCI Center for Selective C-H Functionalization (CHE-1205646), Pfizer, the Research Corporation, Roche, and Yale University is gratefully acknowledged. J.L.W. is grateful for generous funding from Baylor University, the Welch Foundation (Chair, AA-006), and the Cancer Prevention & Research Institute of Texas (CPRIT, R1309).

Attached Files

Accepted Version - nihms-1015478.pdf

Files

nihms-1015478.pdf

Files (2.0 MB)

Name Size
md5:1bc3e980841d2b85519b4d82bc15fba0
2.0 MB Preview Download

Additional details

Identifiers

PMCID
PMC6527366
Eprint ID
64153
Resolver ID
CaltechAUTHORS:20160202-091959130

Funding

Alfred P. Sloan Foundation
Abbott
American Cancer Society
JFRA-523
Amgen
Astellas Pharma
AstraZeneca
Bayer Corporation
Boehringer-Ingelheim
Bristol-Myers Squibb
Caltech
Camille and Henry Dreyfus Foundation
Eli Lilly
Elsa U. Pardee Foundation
GlaxoSmithKline
Johnson & Johnson
Merck
NIH
R01GM080269
Novartis
NSF
CHE-1205646
Pfizer
Research Corporation
Roche
Yale University
Baylor University
Welch Foundation
AA-006
Cancer Prevention & Research Institute of Texas
R1309

Dates

Created
2016-02-02
Created from EPrint's datestamp field
Updated
2022-05-12
Created from EPrint's last_modified field